Summary & Overview
CPT 0230U: Genomic Unity AR Analysis for Androgen Receptor Variants
Headline: New PLA CPT code 0230U designates Genomic Unity® AR Analysis, a proprietary whole genome sequencing test for androgen receptor variants.
Lead: CPT code 0230U identifies a lab-developed, proprietary genomic test—Genomic Unity® AR Analysis from Variantyx Inc.—that uses PCR-free whole genome sequencing on blood or saliva to evaluate the androgen receptor (AR) gene for variants tied to conditions such as spinal and bulbar muscular atrophy (Kennedy disease) and X chromosome inactivation. This PLA code signals a single-source assay with specific clinical utility in hereditary neuromuscular and X-linked conditions.
Why it matters: As precision genomics expands, PLA codes like CPT code 0230U enable distinct billing and tracking for manufacturer- or lab-specific tests. Nationally, payers and providers use PLA codes to identify single-source assays, monitor utilization, and clarify claims handling for specialized genomic diagnostics.
Payers covered: The analysis addresses major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides benchmarks and coding guidance for CPT code 0230U, outlines typical clinical indications and testing workflow, and summarizes payer coverage patterns and policy considerations relevant to proprietary genomic AR testing. It also describes service settings and specimen types, and notes where input data is unavailable.
Billing Code Overview
CPT code 0230U is a Proprietary Laboratory Analyses (PLA) code for the Genomic Unity® AR Analysis from Variantyx Inc. The test evaluates the androgen receptor (AR) gene for variants relevant to conditions such as spinal and bulbar muscular atrophy (Kennedy disease) and X chromosome inactivation, using a blood or saliva specimen.
Service Type: Genetic / genomic diagnostic testing using PCR-free whole genome sequencing with algorithmic analysis
Typical Site of Service: Reference laboratory or specialized diagnostic laboratory; specimen collected at outpatient clinics, physician offices, or collection centers
Clinical & Coding Specifications
Clinical Context
A male patient in his 30s to 50s presents to a neuromuscular clinic with progressive limb and bulbar weakness, repetitive falls, muscle cramps, and early signs of androgen insensitivity such as gynecomastia or reduced fertility. Family history reveals male relatives with similar progressive weakness. The clinician orders the Genomic Unity® AR Analysis (0230U) to evaluate the androgen receptor gene for pathogenic variants, including repeat expansions or point mutations associated with spinal and bulbar muscular atrophy (Kennedy disease) and to assess X chromosome inactivation patterns when clinically relevant.
Specimen collection is blood or saliva obtained in the outpatient clinic or an affiliated phlebotomy/lab facility. The sample is sent to Variantyx Inc. for PCR-free whole genome sequencing (WGS) with algorithmic analysis specific to the AR gene. Results return as a molecular diagnostic report detailing detected variants, interpretation of pathogenicity, and potential implications for diagnosis, prognosis, and familial testing. Typical sites of service include outpatient neurology clinics, genetic counseling offices, independent or hospital-affiliated phlebotomy centers, and reference laboratory processing sites.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Anesthesia for procedures normally requiring general anesthesia | Not typically applicable; use only if anesthesia unrelated to lab testing is documented and billed with lab component per payor rules |